Assessment of the Effect of C-Peptide Level on Na-K ATPase Activity In Individuals with Type II Diabetic Peripheral Neuropathy
Abstract
Background: Both Type 1 and Type 2 diabetes can cause neuropathy, which is a frequent and severe consequence. C-peptide depletion may be partly related to in the occurrence of certain diabetic complications. It has been demonstrated that even a little amount of residual C-peptide has a considerable metabolic advantage.
Objective: The study’s objective was to predict the relation of plasma C-peptide levels in patients with diabetic neuropathy, and its effect on Na-K ATPase activity.
Design and Methods: In this case-control study, 150 individuals have been included: 80 patients with diabetic neuropathy, 40 diabetics without neuropathy and 30 non-diabetic subjects as a control. Patients in the first group were carefully chosen based on their clinical symptoms and nerve conduction studies results. The assessment of plasma C-peptide was done by ELISA, Na-K ATPase enzyme activity by spectrophotometer, and HbA1C by HPLC.
Results: Mean plasma C-peptide level and Erythrocyte Na-K ATPase activity were substantially lower in neuropathy type 2 DM patients compared to diabetes without neuropathy and control (p= 0.002, 0.000 respectively). The negative correlation between C-peptide with HbA1c, and diabetes period were all negligible (p= 0.447,0.098), Even though there was a notable negative correlation with age (p= 0.03). On the other hand, the relationship linking C-peptide and Na-K ATPase enzyme activity was shown to be insignificant (p=0.69).
Conclusions: Diabetic neuropathy is related to a low C-peptide level. The association between C-peptide and Na-K ATPase enzyme activity, on the other hand, was shown to be insignificant. C-peptide HbA1c, and duration of diabetes all had minor negative associations.
How to cite this article:
Al-Rikabi EH, Yasser OM, Mousa MJ. Assessment of the Effect of C-Peptide Level on Na-K ATPase Activity In Individuals with Type II Diabetic Peripheral Neuropathy. J Commun Dis. 2021;53(3):213-219.
DOI: https://doi.org/10.24321/0019.5138.202159
References
Sima AA, Zhang W, Grunberger G. Type 1 diabetic neuropathy and C-peptide. Exp Diabesity Res. 2004
Jan-Mar;5:65-77. [PubMed] [Google Scholar]
Greene DA, Sima AA, Feldman EL, Stevens MJ. Diabetic neuropathy. In: Porte D Jr, Sherwin RS, editors. Ellenbergand Rifkin Diabetes Mellitus. 5th ed. Stanford: Appleton & Lange; 1997, p. 1009-76.
Pirart J. Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients
observed between 1947 and 1973. Diabete Metab. 1977 Jun;3:97-107. [PubMed] [Google Scholar]
Vinik AI, Holland MT, Le Beau JM, Liuzzi FJ, Stansberry KB, Colen LBDiabetic neuropathies. Diabetes Care.
;15:1926-75. [Google Scholar]
Sima AA. Pathological definition and evaluation of diabetic neuropathy and clinical correlations. Can J
Neurol Sci. 1994;21(Suppl 4):513-7. [PubMed] [Google Scholar]
Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A,
Bernardi L, Valensi P; Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on
definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 Oct;33:2285-93.
[PubMed] [Google Scholar]
Mohammed SM, Hasna AS, Makki Al-Hindy HA, Mousa MJ. C-reactive protein is associated with the severity
of periodontal disease - an observational study among acute myocardial infarction patients. Sys Rev Pharm.
;11(10):252-7. [Google Scholar]
Mousa MJ, Al Saffar HS, Al-Hindy HAA. Low level laser (Biophotomodulation) therapy for the treatment of
diabetic foot ulcers with 532 nm KTP laser induces wound healing, fibroblast proliferation and overexpression
of TGF-B. Sys Rev Pharm. 2020;11(6):396-403. [Google Scholar]
Greene DA, Sima AA, Stevens MJ, Feldman EL, Lattimer SA. Complications: neuropathy, pathogenetic
considerations. Diabetes Care. 1992 Dec;15(12):1902-25. [PubMed] [Google Scholar]
Sima AA. Metabolic alterations of peripheral nerve in diabetes. Semin Neurol. 1996;16:129-37. [PubMed]
[Google Scholar]
Sima AA. Diabetic neuropathy; pathogenetic backgrounds, current and future therapies. Expert Rev
Neurother. 2001 Nov;1(2):225-38. [PubMed] [Google Scholar]
Sima AA. New insights into the metabolic and molecular basis for diabetic neuropathy. Cell Mol Life Sci. 2003
Nov;60(11):2445-64. [PubMed] [Google Scholar]
Sima AA. C-peptide and diabetic neuropathy. Expert Opin Investig Drugs. 2003 Sep;12(9):1471-88. [PubMed]
[Google Scholar]
Abed DA, Jasim R, Al-Hindy HA-A, Obaid AW. Cystatin-C in patients with acute coronary syndrome: Correlation
with ventricular dysfunction, and affected coronary vessels. J Contemp Med Sci. 2020;6(1):26-31. [Google
Scholar]
Mayer JP, Zhang F, DiMarchi RD. Insulin structure and function. Biopolymers. 2007;88:687-713. [PubMed]
[Google Scholar]
Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes.
Diabet Med J Br Diabet Assoc Diabet Med. 2013 Jul;30(7):803-17. [PubMed] [Google Scholar]
Matthews DR, Rudenski AS, Burnett MA, Darling P,Turner RC. The half-life of endogenous insulin and
c-peptide in man assessed by Somatostatin suppression. Clin Endocrinol (Oxf). 1985 Jul;23(1):71-9. [PubMed]
[Google Scholar]
Wahren J, Ekberg K, Johansson J, Henriksson M, Pramanik A, Johansson BL, Rigler R, Jörnvall H. Role of
C-peptide in human physiology. Am J Physiol Endocrinol Metab. 2000 May;278(5):E759-68. [PubMed] [Google
Scholar]
Wahren J, Kallas A, Sima AA. The clinical potential of C-peptide replacement in type 1 diabetes. 2012
Apr;61(4):761-72. [PubMed] [Google Scholar]
Rigler R, Pramanik A, Jonasson P, Kratz G, Jansson OT, Nygren P, Stâhl S, Ekberg K, Johansson B, Uhlén
S, Uhlén M, Jörnvall H, Wahren J. Specific binding of proinsulin C-peptide to human cell membranes.
Proc Natl Acad Sci U S A. 1999 Nov;96(23):13318-23. [PubMed] [Google Scholar]
Shafqat J, Juntti-Berggren L, Zhong Z, Ekberg K, Köhler M, Berggren PO, Johansson J, Wahren J, Jörnvall
H. Proinsulin C-peptide and its analogues induce intracellular Ca2+ increases in human renal tubular
cells. Cell Mol Life Sci. 2002 Jul;59(7):1185-9. [PubMed] [Google Scholar]
Zhong Z, Davidescu A, Ehrén I, Ekberg K, Jörnvall H, Wahren J, Chibalin AV. C-peptide stimulates ERK1/2
and JNK MAP kinases via activation of protein kinase C in human renal tubular cells. Diabetologia. 2005
Jan;48(1):187-97. [PubMed] [Google Scholar]
Kitamura T, Kimura K, Makondo K, Furuya DT, Suzuki M, Yoshida T, Saito M. Proinsulin C-peptide increases
nitric oxide production by enhancing mitogen-activated protein-kinase-dependent transcription of endothelial
nitric oxide synthase in aortic endothelial cells of Wistar rats. Diabetologia. 2003 Dec;46(12):1698-705.
[PubMed] [Google Scholar]
Zhong Z, Kotova O, Davidescu A, Ehrén I, Ekberg K, Jörnvall H, Wahren J, Chibalin AV. C-peptide stimulates
Na+, K+-ATPase via activation of ERK1/2 MAP kinases in human renal tubular cells. Cell Mol Life Sci. 2004
Nov;61(21):2782-90. [PubMed] [Google Scholar]
Luppi P, Kallas A, Wahren J. Can C-peptide mediated anti-inflammatory effects retard the development
of microvascular complications of type 1 diabetes? Diabetes Metab Res Rev. 2013 Jul;29(5):357-62.[PubMed] [Google Scholar]
Bhatt MP, Lim YC, Kim YM, Ha KS. C-peptide activates AMPKa and prevents ROS-mediated mitochondrial
fission and endothelial apoptosis in diabetes. Diabetes. 2013 Nov;62(11):3851-62. [PubMed] [Google Scholar]
Qiao X, Zheng H, Zhang S, Liu S, Xiong Q, Mao F, Zhang Z, Wen J, Ye H, Li Y, Lu B. C-peptide is independent
associated with diabetic peripheral neuropathy: a community-based study. Diabetol Metab Syndr. 2017
Feb;9:12. [PubMed] [Google Scholar]
Whelchel AE, McKay TB, Priyadarsini S, Rowsey T, Karamichos D. Association between Diabetes and
Keratoconus: A Retrospective Analysis Sci Rep. 2019 Sep;9(1):13808. [PubMed] [Google Scholar]
McCartney MD, Robertson DP, Wood TO, McLaughlin BJ. ATPase pump site density in human dysfunctional
corneal endothelium. Invest Ophthalmol Vis Sci. 1987 Dec;28(12):1955-62. [PubMed] [Google Scholar]
McKay TB, Priyadarsini S, Karamichos D. Mechanisms of collagen crosslinking in diabetes and keratoconus.
Cells. 2019;8(10):1239. [PubMed] [Google Scholar]
Kazaili A, Abdul-Amir Al-Hindy H, Madine J, Akhtar R. Nano-scale stiffness and collagen fibril deterioration:
probing the cornea following enzymatic degradation using peakforce-QNM AFM. Sensors (Basel). 2021
Feb;21(5):1629. [PubMed] [Google Scholar]
Al-Rikabia EH, Mousa MJ, Yasser OM. Estimation of NaK - ATPase enzyme activity and endogenous digitalis
in patients with diabetic neuropathy. NeuroQuantology. 2021;19(5):95-103.
Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies.
Bioinformatics. 2006 Aug;22(15):1928-9. [PubMed] [Google Scholar]
Nisar MU, Asad A, Waqas A, Ali N, Nisar A, Qayyum MA, Maryam H, Javaid M, Jamil M. Association of
diabetic neuropathy with duration of type 2 diabetes and glycemic control. Cureus. 2015 Aug;7(8):e302.
[PubMed] [Google Scholar]
Qiao X, Zheng H, Zhang S, Liu S, Xiong Q, Mao F, Zhang Z, Wen J, Ye H, Li Y, Lu B. C-peptide is independent
associated with diabetic peripheral neuropathy: a community-based study. Diabetol Metab Syndr. 2017
Feb;9:12. [PubMed] [Google Scholar]
Masoom MM, Albiladi F. C-Peptide as a marker for diabetic nephropathy. Intern Med. 2017;7:245.
Galuska D, Pirkmajer S, Barrès R, Ekberg K, Wahren J, Chibalin AV. C-peptide increases Na, K-ATPase
expression via PKC- and MAP kinase-dependent activation of transcription factor ZEB in human renal
tubular cells. PLoS One. 2011;6(12):e28294. [PubMed] [Google Scholar]
Cho YN, Lee KO, Jeong J, Park HJ, Kim SM, Shin HY, Hong JM, Ahn CW, Choi YC. The role of insulin resistance in
diabetic neuropathy in Koreans with type 2 diabetes mellitus: a 6-year follow-up study. Yonsei Med J. 2014
May;55(3):700-8. [PubMed] [Google Scholar]
Adam KM, Tajelsir S, Aowad DA. Correlation between C-peptide level and chronic microvascular complications
in type 2 diabetes mellitus Sudanese patients. Open Access Lib J. 2016;3:e2634. [Google Scholar]
De La Tour DD, Raccah D, Jannot MF, Coste T, Rougerie C, Vague P. Erythrocyte Na/K ATPase activity and diabetes: relationship with C-peptide level. Diabetologia. 1998 Sep;41(9):1080-4. [PubMed] [Google Scholar]
Koc B, Erten V, Yilmaz MI, Sonmez A, Kocar IH. The relationship between red blood cell Na/K-ATPase
activities and diabetic complications in patients with type 2 diabetes mellitus. Endocrine. 2003
Aug;21(3):273-8. [PubMed] [Google Scholar]
Sari R, Balci MK. Relationship between C-peptide and chronic complications in type-2 diabetes mellitus. J
Natl Med Assoc. 2005 Aug;97(8):1113-8. [PubMed] [Google Scholar]
Klein R, Klein BE, Moss SE. The Wisconsin epidemiologic study of diabetic retinopathy. XVI. The relationship
of C-peptide to the incidence and progression of diabetic retinopathy. Diabetes. 1995 Jul;44(7):796-
[PubMed] [Google Scholar]
Copyright (c) 2021 Author's
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
